DR. LEWIS J RUBIN, M.D.
Osteopathic Medicine at Campus Point Dr, La Jolla, CA
License number
California G85002
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G85002
Category
Osteopathic Medicine
Type
Critical Care Medicine
License number
California G85002
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
9300 Campus Point Dr, La Jolla, CA 92037
Phone
(858) 657-8700
Organization information
See more information about LEWIS J RUBIN at bizstanding.comLewis J. Rubin, M.D., A Professional Medical Corporation
5550 Caminito Genio, La Jolla, CA 92037
Industry:
Health/Allied Services
Registration:
Jun 6, 2012
State ID:
03477416
Business type:
Articles of Incorporation
President:
Lewis J. Rubin (President)
Professional information
Lewis J Rubin, La Jolla CA
Specialties:
Internal Medicine, Pulmonary Disease, Critical Care Medicine, Cardiovascular Disease
Work:
Ucsd Medical Group
9300 Campus Point Dr, La Jolla, CA 92037 UC San Diego Health System
200 W Arbor Dr, San Diego, CA 92103
9300 Campus Point Dr, La Jolla, CA 92037 UC San Diego Health System
200 W Arbor Dr, San Diego, CA 92103
Education:
Yeshiva University (1975)
Emeritus Professor At Ucsd Medical Center
Position:
Professor at UCSD Medical Center
Location:
La Jolla, California
Industry:
Medical Practice
Work:
UCSD Medical Center
-
Professor
Regulating Expression Of Transient Receptor Potential Channel Genes
US Patent:
2008011, May 22, 2008
Filed:
Jan 17, 2006
Appl. No.:
11/814038
Inventors:
Carmelle Remillard - San Diego CA, US
Lewis J. Rubin - La Jolla CA, US
Ying Yu - Lake Forest CA, US
Jason X.J. Yuan - San Diego CA, US
Lewis J. Rubin - La Jolla CA, US
Ying Yu - Lake Forest CA, US
Jason X.J. Yuan - San Diego CA, US
International Classification:
C12Q 1/68, A61K 39/395, A61K 31/7088, A61K 38/02, C07H 21/02, C12N 15/63, C12N 15/11, C07K 16/00, C07K 2/00, G01N 33/53
US Classification:
4241301, 435 6, 514 44, 514 2, 536 245, 5303871, 5303881, 4353201, 436501
Abstract:
The present invention relates to compositions related to a polynucleotide encoding a transient receptor potential cation gene. Also disclosed is the use of this polynucleotide, its homologs, fragments, variants and its resultant polypeptides in the diagnosis, prevention and treatment of disease, particularly idiopathic pulmonary arterial hypertension (IPAH). This invention also teaches the use of these polynucleotides and polypeptides as assays for drug discovery and therapies.
Method Of Determining Vasoreactivity Using Inhaled Nitric Oxide
US Patent:
2013030, Nov 21, 2013
Filed:
Jan 7, 2013
Appl. No.:
13/735558
Inventors:
GeNO LLC - , US
Robert F. Roscigno - Melbourne Beach FL, US
David H. Fine - Cocoa Beach FL, US
Lewis J. Rubin - La Jolla CA, US
Robert F. Roscigno - Melbourne Beach FL, US
David H. Fine - Cocoa Beach FL, US
Lewis J. Rubin - La Jolla CA, US
International Classification:
A61B 5/026, A61K 33/00, A61M 16/12
US Classification:
424718, 600508, 12820312
Abstract:
A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction.